NASDAQ:BNGO

Bionano Genomics Stock News

Healthcare > Medical - Diagnostics & Research

Buy BNGO

*Your capital is at risk

$1.30

+0.0400 (+3.17%)

At Close: Jun 03, 2026

The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions

12:00am, Thursday, 18'th Jun 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) Adverum Biotechnologies Inc...

The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx

12:00am, Sunday, 14'th Jun 2020

Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-...

Bionano Genomics to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on June 18

12:46pm, Friday, 12'th Jun 2020

SAN DIEGO, June 12, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.

Data Presented at European Society of Human Genetics (ESHG) Conference Shows Saphyr System has 100% Concordance with Standard Cytogenetics in Leukemias and Constitutional Aberrations

12:00pm, Thursday, 11'th Jun 2020

Bionano Genomics, Inc. (BNGO) today announced that three top cytogeneticists from leading institutions in The Netherlands and Germany presented data at the 2020 European Society of Human Genetics (ESH

Bionano Genomics Announces Issuance of US Patent for Combined Nanochannel-Nanopore Device

12:00pm, Monday, 08'th Jun 2020

Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the United States Patent and Trademark Office will issue US Patent No. 10,676,352 on June 9th, 2020.

What Makes Bionano Genomics, Inc. (BNGO) a New Strong Buy Stock

04:00pm, Thursday, 28'th May 2020

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Bionano to Participate in Maxim Group’s Covid-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing

12:00pm, Wednesday, 27'th May 2020

Bionano Genomics, Inc. (BNGO) today announced that Erik Holmlin, Ph.D., CEO of Bionano, will participate on a panel entitled: “Testing and Susceptibility – Clearing the Air,” during the virtual

Cancer Genomics Consortium Members Demonstrate 100% Concordance Between Bionano Saphyr and Gold Standard Cytogenetics in Leukemia

12:00pm, Tuesday, 19'th May 2020

Bionano Genomics, Inc. (BNGO) announced that in an online presentation hosted by the Cancer Genomics Consortium (CGC) on May 12, 2020, Dr. Brynn Levy from Columbia University and Dr. Rashmi Kanagal-Sh

Bionano Genomics to Report First Quarter 2020 Financial Results on June 18, 2020

08:30pm, Thursday, 14'th May 2020

Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome an

Bionano Genomics Adds Healthcare and Genomics Industry Experts with Experience in Commercialization and Reimbursement to Its Board of Directors

09:00pm, Monday, 04'th May 2020

Bionano Genomics, Inc. (BNGO) today announced the appointment of Hannah Mamuszka and Yvonne Linney, PhD, to its board of directors. Junfeng Wang, who originally joined the company’s board as a repr

Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests

12:00pm, Wednesday, 22'nd Apr 2020

Bionano Genomics, Inc. (BNGO) announced that the University of Iowa Hospitals and Clinics (UIHC) will switch their method of clinical molecular testing for patients with presumed Facioscapulohumeral M

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by